Article
Biotechnology & Applied Microbiology
Jiyeon Kweon, Jung-Ki Yoon, An-Hee Jang, Ha Rim Shin, Ji-Eun See, Gayoung Jang, Jong-Il Kim, Yongsub Kim
Summary: The engineered prime editors leverage various PAM-flexible Cas9 variants to broaden the range of target sites and achieve high editing activity, successfully generating multiple types of mutations in cells. Additionally, they successfully introduce mutations such as BRAF V600E that cannot be induced by conventional prime editors, expanding the applicability of CRISPR-based prime editing technologies in biological research.
Article
Multidisciplinary Sciences
Emmarie. C. C. Ryan, Leslie. M. M. Huggins, Joshua. D. D. Podlevsky
Summary: CRISPR arrays and Cas proteins are adaptive immune systems in bacteria and archaea, defending against genetic elements. The reprogrammable guide RNA of single effector CRISPR-Cas systems greatly facilitates gene-editing but complicates PCR tests. These systems are derived from human microflora and pathogens, making detection of gene-editor exposure difficult. To overcome false positives, a DNA displacement assay has been developed to specifically detect gene-editors without cross-reacting with bacterial CRISPRs.
SCIENTIFIC REPORTS
(2023)
Article
Biotechnology & Applied Microbiology
Yerin Jin, Sora Yu, Jing-Jing Liu, Eun Ju Yun, Jae Won Lee, Yong-Su Jin, Kyoung Heon Kim
Summary: In this study, the probiotic yeast S. boulardii was engineered to produce health-beneficial neoagarooligosaccharides (NAOSs) by expressing an endo-type beta-agarase, BpGH16A, derived from a human gut bacterium Bacteroides plebeius. The results suggest that engineered S. boulardii can be considered a microbial cell factory for producing useful substances in the human gut, with successful production of health-benefiting NeoDP4 from agarose.
MICROBIAL CELL FACTORIES
(2021)
Article
Biochemistry & Molecular Biology
Nan Wei, Lu Shang, Jing Liu, Mi Wang, Yingchun Liu, Chuangang Zhu, Chenzhong Fei, Lifang Zhang, Fayu Yang, Feng Gu
Summary: Researchers have identified a new gene editing tool called SauriCas9, which is more flexible and has enhanced targeting specificity compared to the traditional tool SaCas9, potentially reducing off-target effects.
Article
Biochemistry & Molecular Biology
Nan Wei, Lu Shang, Jing Liu, Mi Wang, Yingchun Liu, Chuangang Zhu, Chenzhong Fei, Lifang Zhang, Fayu Yang, Feng Gu
Summary: SauriCas9 is a gene editing tool with high efficiency and two engineered variants (SauriCas9-HF1 and SauriCas9-HF2) significantly improve the specificity of genome editing by introducing key mutations.
Article
Biotechnology & Applied Microbiology
Siqi Gao, Yao Wang, Tao Qi, Jingjing Wei, Ziying Hu, Jingtong Liu, Shuna Sun, Huihui Liu, Yongming Wang
Summary: In this study, the PAM sequences of CjCas9 and its orthologs, Hsp1Cas9, Hsp2Cas9, and CcuCas9, were investigated. It was found that they recognized N4RAA, N4CNA, and N4CY PAMs, respectively. By analyzing the crystal structure of CjCas9, eight mutations were identified to improve specificity and generate a high-fidelity Hsp1-Hsp2Cas9-Y. These natural and engineered Cas9 nucleases enabled efficient genome editing in multiple mammalian cells, expanding the DNA targeting scope.
Article
Medicine, Research & Experimental
Miffy H. Y. Cheng, Cedric A. Brimacombe, Rein Verbeke, Pieter R. Cullis
Summary: In this brief perspective, the authors provide a description of key events in the history of lipid-based nanomedicine, focus on Canadian contributions, and outline potential areas where lipid nanoparticle technology could revolutionize the future of medicine.
MOLECULAR PHARMACEUTICS
(2022)
Article
Chemistry, Multidisciplinary
Xiao Liu, Zhengcong Cao, Weizhong Wang, Cheng Zou, Yingwen Wang, Luxiang Pan, Bo Jia, Kuo Zhang, Wangqian Zhang, Weina Li, Qiang Hao, Yingqi Zhang, Wei Zhang, Xiaochang Xue, Wei Lin, Meng Li, Jintao Gu
Summary: This study identified glutathione synthetase (GSS) as a potential regulator of radioresistance in glioblastoma (GBM) through in vivo loss-of-function genome-wide CRISPR screening and transcriptome analyses. High GSS levels were associated with poor prognosis and relapse in glioma patients. The study also developed a gene editing delivery system that could target the blood-brain barrier (BBB) and tumor for potential therapeutic translation.
Article
Biochemistry & Molecular Biology
Guoxu Song, Fei Zhang, Chunhong Tian, Xing Gao, Xiaoxiao Zhu, Dongdong Fan, Yong Tian
Summary: This study identified novel anti-CRISPR families that have the ability to inhibit Cas9 activity and even control genome editing post-translationally. By studying different Acr variants and developing chemically inducible control, new avenues for CRISPR-Cas9 applications have been established.
NUCLEIC ACIDS RESEARCH
(2022)
Article
Multidisciplinary Sciences
Lin Zhao, Sabrina R. T. Koseki, Rachel A. Silverstein, Nadia Amrani, Christina Peng, Christian Kramme, Natasha Savic, Martin Pacesa, Tomas C. Rodriguez, Teodora Stan, Emma Tysinger, Lauren Hong, Vivian Yudistyra, Manvitha R. Ponnapati, Joseph M. Jacobson, George M. Church, Noah Jakimo, Ray Truant, Martin Jinek, Benjamin P. Kleinstiver, Erik J. Sontheimer, Pranam Chatterjee
Summary: In this study, a chimeric enzyme SpRYc with highly flexible PAM preference was generated by combining the PAM-interacting domain of SpRY and the N-terminus of Sc++, leveraging properties of both enzymes. SpRYc showed the ability to specifically edit diverse PAMs and disease-related loci, highlighting the power of integrative protein design for Cas9 engineering.
NATURE COMMUNICATIONS
(2023)
Review
Multidisciplinary Sciences
Darrell J. Irvine, Marcela V. Maus, David J. Mooney, Wilson W. Wong
Summary: Immune cell therapy is a promising approach to treating diseases, especially cancer, by engineering immune cells to recognize and respond to specific conditions. This therapy has already been approved for clinical use and continues to be developed and tested in various applications.
Review
Chemistry, Multidisciplinary
Ke Yi, Huimin Kong, Yeh-Hsing Lao, Di Li, Rachel L. Mintz, Tianxu Fang, Guojun Chen, Yu Tao, Mingqiang Li, Jianxun Ding
Summary: CRISPR/Cas9 gene-editing technology has great potential in cancer treatment, but limitations of viral delivery have led to the development of non-viral nanomaterials. Optimizing the packaging capacity, pharmacokinetics, and targetability of non-viral CRISPR/Cas9 nanoformulations can enhance the safety and efficacy of cancer therapy.
ADVANCED MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Hyo-Ju Jang, Hye-Jeong Park, Hong Seok Choi, Hyun Jun Jung, Tae-Hwan Kwon
Summary: This study aimed to establish mpkCCDc14 cells constitutively expressing V2R and AQP2 via CRISPR/Cas9-mediated genome engineering technology. The results showed that these cells had higher abundance of AQP2 protein in the absence of stimulation and exhibited normal response to dDAVP stimulation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, Research & Experimental
Kiran Musunuru
Summary: The rapid development of genome-editing technologies has opened up new possibilities for treating cardiovascular diseases. This review discusses various genome-editing approaches and their potential applications in cardiovascular disease treatment, providing insights into the path from technology development to clinical trials.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Biotechnology & Applied Microbiology
James S. Donaldson, Matthew P. Dale, Susan J. Rosser
Summary: By decoupling cell growth and biotherapeutic production, it is possible to enhance production efficiency and improve cell growth characteristics, particularly for difficult-to-express proteins.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)